Nicola Fusco: CtDNA Interpretation in HR+/HER2- Metastatic Breast Cancer
2h agoen
Source
OncoDailyNicola Fusco: CtDNA Interpretation in HR+/HER2- Metastatic Breast Canceroncodaily.comNicola Fusco, Director of the Division of Pathology at IEO European Institute of Oncology, shared a post on LinkedIn: “I’m pleased to share our latest Editorial, co-authored with my friend Umberto […]
You might also wanna read
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
doi.org·22h ago
Estudo vê economia com teste genômico no câncer de mama
Extra Online·1d ago
Una nueva prueba detecta el cáncer de boca en menos de una hora: podría evitar hasta el 90% de las biopsias quirúrgicas
Infobae·5h ago
RCSI and UCD study identifies immune markers to reduce unnecessary chemotherapy in breast cancer patients
Research led by RCSI University of Medicine and Health Sciences and University College Dublin has identified immune markers that could help
rcsi.com·15d agoExplainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer
doi.org·11d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.